Pharmaxis (Pharmaxis) Change In Inventory : $0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Pharmaxis Change In Inventory?

Pharmaxis's change in inventory for the quarter that ended in Dec. 2023 was $0.00 Mil. It means Pharmaxis's inventory stayed the same from Jun. 2023 to Dec. 2023 .

Pharmaxis's change in inventory for the fiscal year that ended in Jun. 2023 was $0.00 Mil. It means Pharmaxis's inventory stayed the same from Jun. 2022 to Jun. 2023 .

Pharmaxis's Total Inventories for the quarter that ended in Dec. 2023 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year. Pharmaxis's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.00.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Pharmaxis Change In Inventory Historical Data

The historical data trend for Pharmaxis's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmaxis Change In Inventory Chart

Pharmaxis Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Change In Inventory

Get a 7-Day Free Trial

Pharmaxis Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Inventory	Get a 7-Day Free Trial															-	-	-	-	-

Pharmaxis Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

Pharmaxis (OTCPK:PXSLY) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Pharmaxis's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0.5505	/	0	*	365 / 2
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Pharmaxis's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0.5505
	=	0.00

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Pharmaxis's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0.5505	/	0
	=	N/A

Pharmaxis Change In Inventory Related Terms

Thank you for viewing the detailed overview of Pharmaxis's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmaxis (Pharmaxis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pharmaxis Ltd (OTCPK:PXSLY) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

UUDA:Germany SNT:Australia

Address

20 Rodborough Road, Locked Bag 5015, Frenchs Forest, Sydney, NSW, AUS, 2086

Website

https://www.pharmaxis.com.au

Syntara Ltd Formerly Pharmaxis Ltd is an Australia based pharmaceutical research company engaged in the research, development, and commercialization of human healthcare products for the treatment and management of fibrotic and inflammatory diseases. The firm's research efforts are focused on discovering drugs to treat inflammatory and fibrotic diseases such as NASH, pulmonary fibrosis, kidney and liver fibrosis and cancer from its amine oxidase inhibitor chemistry platform. Its product pipeline also includes Orbital and ASM8. The operating segments are Mannitol respiratory business and New Drug Development. It generates maximum revenue from Mannitol respiratory business segment.

Pharmaxis (Pharmaxis) Headlines

From GuruFocus

Pharmaxis Commences Final Cohort Dosing in Bone Marrow Cancer Phase 1c Trial

By PRNewswire PRNewswire • 08-04-2021

FDA Bronchitol Approval to Generate Cash Flows for Pharmaxis

By Business Wire Business Wire • 11-02-2020

Pharmaxis Cancer Drug Decreases Tumour Burden in Pre Clinical Liver Cancer Model

By PRNewswire PRNewswire • 08-05-2021

FDA Clears Pharmaxis Cancer Drug to Progress to Phase 2 Study in Liver Cancer

By PRNewswire PRNewswire • 11-09-2021

Pharmaxis Treatment to Prevent Wound and Burns Scars Clears Phase 1 Trial

By PRNewswire PRNewswire • 08-31-2021

Pharmaxis Cleared To Progress To Phase 2 Bone Marrow Cancer Trial

By PRNewswire PRNewswire • 10-05-2021